NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY

Plexiform neurofibromas (PNs) can cause significant disfigurement, compression of vital structures, neurologic dysfunction, and pain. MEK pathway inhibition results in significant PN shrinkage in neurofibromatosis type 1 (NF1) mouse models of PN. We evaluated the efficacy of the MEK inhibitor, PD032...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Weiss, Brian, Plotkin, Scott, Widemann, Brigitte, Tonsgard, James, Blakeley, Jaishri, Allen, Jeffrey, Schorry, Elizabeth, Korf, Bruce, Rosser, Tena, Goldman, Stewart, Vinks, Alexander, Cutter, Gary, Dombi, Eva, Ratner, Nancy, Packer, Roger, Fisher, Michael
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2018
Pynciau:
Abstracts
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012484/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.514
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg